Fulminant Myocarditis with VA-ECMO Support: Clinical Characteristics and Prognosis in a Cohort from a Tertiary Transplant Center
Abstract
1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hang, W.; Chen, C.; Seubert, J.M.; Wang, D.W. Fulminant myocarditis: A comprehensive review from etiology to treatments and outcomes. Signal Transduct. Target. Ther. 2020, 5, 287. [Google Scholar] [CrossRef] [PubMed]
- Lorusso, R.; Centofanti, P.; Gelsomino, S.; Barili, F.; Di Mauro, M.; Orlando, P.; Botta, L.; Milazzo, F.; Dato, G.A.; Casabona, R.; et al. Venoarterial Extracorporeal Membrane Oxygenation for Acute Fulminant Myocarditis in Adult Patients: A 5-Year Multi-Institutional Experience. Ann. Thorac. Surg. 2016, 101, 919–926. [Google Scholar] [CrossRef]
- Gordón, M.; Gimeno, R.; Pérez-Esteban, F.; Fuset, M.P. Utilización del oxigenador de membrana extracorpórea en la miocarditis con shock cardiogénico refractario: Resultados iniciales de una experiencia pionera en España [Utilization of the extracorporeal membrane oxygenator in myocarditis with refractory cardiogenic shock: Preliminary results from a Spanish pioneering expe-rience]. Med. Clin. 2013, 140, 232–233. [Google Scholar]
- Cheng, R.; Hachamovitch, R.; Kittleson, M.; Patel, J.; Arabia, F.; Moriguchi, J.; Esmailian, F.; Azarbal, B. Clinical outcomes in fulminant myocarditis requiring extracorporeal membrane oxygenation: A weighted meta-analysis of 170 patients. J. Card. Fail. 2014, 20, 400–406. [Google Scholar] [CrossRef] [PubMed]
- McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021, 42, 3599–3726. [Google Scholar] [CrossRef]
- Ammirati, E.; Frigerio, M.; Adler, E.D.; Basso, C.; Birnie, D.H.; Brambatti, M.; Friedrich, M.G.; Klingel, K.; Lehtonen, J.; Moslehi, J.J.; et al. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document. Circ. Heart Fail. 2020, 13, e007405. [Google Scholar] [CrossRef]
- Khwaja, A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin. Pract. 2012, 120, c179–c184. [Google Scholar] [CrossRef]
- Ammirati, E.; Cipriani, M.; Lilliu, M.; Sormani, P.; Varrenti, M.; Raineri, C.; Petrella, D.; Garascia, A.; Pedrotti, P.; Roghi, A.; et al. Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation 2017, 136, 529–545. [Google Scholar] [CrossRef]
- Kociol, R.D.; Cooper, L.T.; Fang, J.C.; Moslehi, J.J.; Pang, P.S.; Sabe, M.A.; Shah, R.V.; Sims, D.B.; Thiene, G.; Vardeny, O.; et al. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association. Circulation 2020, 141, E69–E92. [Google Scholar] [CrossRef]
- Kanaoka, K.; Onoue, K.; Terasaki, S.; Nakano, T.; Nakai, M.; Sumita, Y.; Hatakeyama, K.; Terasaki, F.; Kawakami, R.; Iwanaga, Y.; et al. Features and Outcomes of Histologically Proven Myocarditis With Fulminant Presentation. Circulation 2022, 146, 1425–1433. [Google Scholar] [CrossRef] [PubMed]
- Veronese, G.; Ammirati, E.; Cipriani, M.; Frigerio, M. Fulminant myocarditis: Characteristics, treatment, and outcomes. Anatol. J. Cardiol. 2018, 19, 279–286. [Google Scholar] [CrossRef]
- Pan, C.; Zhao, J.; Zhang, B.; Lu, A.; Bai, M. Influence of extracorporeal membrane oxygenation on in-hospital survival and prognosis of adult pa-tients with fulminant myocarditis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2022, 34, 1031–1035. (In Chinese) [Google Scholar] [CrossRef]
- Ammirati, E.; Veronese, G.; Cipriani, M.; Moroni, F.; Garascia, A.; Brambatti, M.; Adler, E.D.; Frigerio, M. Acute and Fulminant Myocarditis: A Pragmatic Clinical Approach to Diagnosis and Treatment. Curr. Cardiol. Rep. 2018, 20, 114. [Google Scholar] [CrossRef]
- Moslehi, J.; Lichtman, A.H.; Sharpe, A.H.; Galluzzi, L.; Kitsis, R.N. Immune checkpoint inhibitor–associated myocarditis: Manifestations and mechanisms. J. Clin. Investig. 2021, 131, e145186. [Google Scholar] [CrossRef]
- Chou, H.-W.; Wang, C.-H.; Lin, L.-Y.; Chi, N.-H.; Chou, N.-K.; Yu, H.-Y.; Chen, Y.-S. Prognostic factors for heart recovery in adult patients with acute fulminant myocarditis and cardiogenic shock supported with extracorporeal membrane oxygenation. J. Crit. Care 2020, 57, 214–219. [Google Scholar] [CrossRef]
- Zhang, X.; Wang, S.; Jia, J.; Li, W.; Li, J. The use of extracorporeal membrane oxygenation in the treatment of fulminant myocarditis: Current progress and clinical outcomes. Microvasc. Res. 2021, 137, 104190. [Google Scholar] [CrossRef] [PubMed]
- Toda, K.; Ako, J.; Hirayama, A.; Kinugawa, K.; Kobayashi, Y.; Ono, M.; Nishimura, T.; Sato, N.; Shindo, T.; Takayama, M.; et al. Outcomes of Veno-Arterial Extracorporeal Membrane Oxygenation With Percutaneous Left Ventricular Unloading in Fulminant Myocarditis. Asaio J. 2024, 70, 258–263. [Google Scholar] [CrossRef] [PubMed]
- Burkhoff, D.; Sayer, G.; Doshi, D.; Uriel, N. Hemodynamics of Mechanical Circulatory Support. J. Am. Coll. Cardiol. 2015, 66, 2663–2674. [Google Scholar] [CrossRef]
- Ait-Ali, L.; Martins, D.S.; Khraiche, D.; Festa, P.; Barison, A.; Martini, N.; Benadjaoud, Y.; Anjos, R.; Boddaert, N.; Bonnet, D.; et al. Cardiac MRI Prediction of Recovery in Children With Acute Myocarditis. JACC Cardiovasc. Imaging 2021, 14, 693–695. [Google Scholar] [CrossRef] [PubMed]
- Vidusa, L.; Kalejs, O.; Maca-Kaleja, A.; Strumfa, I. Role of Endomyocardial Biopsy in Diagnostics of Myocarditis. Diagnostics 2022, 12, 2104. [Google Scholar] [CrossRef]
- Brener, M.I.; Rosenblum, H.R.; Burkhoff, D. Pathophysiology and Advanced Hemodynamic Assessment of Cardiogenic Shock. Methodist DeBakey Cardiovasc. J. 2020, 16, 7–15. [Google Scholar] [CrossRef]
- Hao, T.; Chen, L.; Wu, C.; Xie, J.; Li, C.; Xie, H.; Du, Z.; Liu, L.; Yang, Y.; Liu, S.; et al. Impact of renal complications on outcome in adult patients with acute fulminant myocarditis receiving venoarterial extracorporeal membrane oxygenation: An analysis of nationwide CSECLS database in China. Ann. Intensive Care 2023, 13, 93. [Google Scholar] [CrossRef]
- Zhang, J.; Gao, C.; Zhang, J.; Ye, F.; Guo, S. Development and validation of a prognostic model for early mortality risk in patients with fulminant myocarditis. Cardiovasc. Diagn. Ther. 2025, 15, 318–335. [Google Scholar] [CrossRef]
- Alba, A.C.; Foroutan, F.; Buchan, T.A.; Alvarez, J.; Kinsella, A.; Clark, K.; Zhu, A.; Lau, K.; McGuinty, C.; Aleksova, N.; et al. Mortality in patients with cardiogenic shock supported with VA ECMO: A systematic review and meta-analysis evaluating the impact of etiology on 29,289 patients. J. Heart Lung Transplant. 2021, 40, 260–268. [Google Scholar] [CrossRef]
- Li, C.; Cai, T.; Xie, H.; Wang, L.; Yang, F.; Du, Z.; Hong, X.; Zhou, C.; Li, Y.; Qiu, H.; et al. Risk factors and outcomes for patients with bleeding complications receiving extracorporeal membrane oxygenation: An analysis of the Chinese Extracorporeal Life Support Registry. Artif. Organs 2022, 46, 2432–2441. [Google Scholar] [CrossRef]
- Liao, X.; Li, B.; Cheng, Z. Extracorporeal membrane oxygenation in adult patients with acute fulminant myocarditis: Clinical outcomes and risk factor analysis. Herz 2018, 43, 728–732. [Google Scholar] [CrossRef]
- Chen, Y.; Chen, J.; Liu, C.; Xu, Z.; Chen, Y. Impact factors of POCUS-guided cannulation for peripheral venoarterial extracorporeal membrane oxygenation: One single-center retrospective clinical analysis. Medicine 2022, 101, e29489. [Google Scholar] [CrossRef]
- Liu, L.; Yang, X.; Gu, Y.; Jiang, T.; Xu, J.; Xu, M. Predictive Value of the Age, Creatinine, and Ejection Fraction (ACEF) Score in Patients With Acute Fulminant Myocarditis. Front. Physiol. 2021, 12, 596548. [Google Scholar] [CrossRef] [PubMed]
- Ammirati, E.; Veronese, G.; Bottiroli, M.; Wang, D.W.; Cipriani, M.; Garascia, A.; Pedrotti, P.; Adler, E.D.; Frigerio, M. Update on acute myocarditis. Trends Cardiovasc. Med. 2021, 31, 370–379. [Google Scholar] [CrossRef] [PubMed]
- Veraar, C.; Schwarz, S.; Thanner, J.; Direder, M.; Boehm, P.M.; Harnoncourt, L.; Ortmayr, J.; Veraar, C.; Mascherbauer, J.; Klepetko, W.; et al. Transient perioperative inflammation following lung transplantation and major thoracic surgery with elective extracorporeal support: A prospective observational study. Ann. Transl. Med. 2021, 9, 385. [Google Scholar] [CrossRef] [PubMed]
- Ankersmit, H.; Ullrich, R.; Moser, B.; Hoetzenecker, K.; Hacker, S.; German, P.; Krenn, C.; Horvat, R.; Grimm, M.; Wolner, E.; et al. Recovery from giant cell myocarditis with ECMO support and utilisation of polyclonal antithymocyte globulin: A case report. Thorac. Cardiovasc. Surg. 2006, 54, 278–280. [Google Scholar] [CrossRef] [PubMed]
- Marcus, J.E.; Shah, A.; Peek, G.J.; MacLaren, G. Nosocomial Infections in Adults Receiving Extracorporeal Membrane Oxygenation: A Review for Infectious Diseases Clinicians. Clin. Infect. Dis. 2024, 79, 412–419. [Google Scholar] [CrossRef] [PubMed]
Recovery (n: 10) | No Recovery (n: 12) | p | Total (n = 22) | |
---|---|---|---|---|
Age (years) * | 47 ± 14 | 52 ± 8 | 0.30 | 49.7 ± 11 |
Male (n, %) | 5 (50) | 3 (25) | 0.37 | 8 (36.4) |
Comorbidities (n, %) | ||||
HT | 1 (10) | 2 (16.6) | 0.48 | 3 (13.6) |
DL | 1 (10) | 1 (8.3) | 0.75 | 2 (9.1) |
DM | 0 (0) | 1 (8.3) | 0.95 | 1 (4.5) |
Active smoking | 1 (10) | 1 (8.3) | 0.95 | 2 (9.1) |
CKD | 1 (10) | 2 (16.6) | 0.67 | 3 (13.6) |
Weight (kg) * | 56 ± 11 | 61 ± 13 | 0.40 | 58.7 ± 12.1 |
Height (cm) * | 173 ± 13 | 173 ± 10 | 0.97 | 173 ± 11.4 |
Previous CV disease | 1 (10) | 3 (25) | 0.59 | 4 (18.2) |
Time from symptom onset to ICU admission (days) * | 5.2 ± 5.4 | 6.1 ± 3.7 | 0.56 | 5.7 ± 4.5 |
Recovery (n = 10) | No Recovery (n = 12) | p | Total (n = 22) | |
---|---|---|---|---|
Clinical presentation (n, %): Cardiogenic shock (low output) Arrhythmic Other | 7 (70) 2 (20) 1 (10) | 12 (100) 0 (0) 0 (0) | 0.06 | 19 (86.4) 2 (9.1) 1 (4.5) |
INTERMACS level (n, %) I II | 1 (10) 9 (90) | 4 (33) 8 (67) | 0.21 | 5 (22.7) 17 (77.3) |
ECMO hours * | 188 ± 103 | 328 ± 225 | 0.03 | 267 ± 281 |
Intubation required (n, %) | 8 (80) | 11 (91.6) | 0.54 | 19 (86.4) |
Duration of invasive mechanical ventilation (hours) * | 162 ± 68 | 210 ± 103 | 0.11 | 189 ± 90 |
Left ventricular assist device (LVAD) (n, %): Impella Intra-aortic balloon pump | 3 (30) 0 (0) 3 (100) | 6 (50) 3 (50) 3 (50) | 0.34 | 9 (40.9) 3 (13.6) 6 (27.2) |
LVAD duration (hours) | 197 ± 175 | 245 ± 147 | 0.701 | 223 ± 161 |
Catheterization | 5 (50) | 10 (83.3) | 0.09 | 15 (68.2) |
Cardiac MRI (n, %): Fibrosis Edema | 9 (90) 4 (44.4) 8 (88.8) | 6 (50) 6 (100) 3 (50) | 0.12 0.03 0.28 | 15 (68.18) 10 (45.45) 11 (50) |
Endomyocardial biopsy (n,%) | 1 (10) | 1 (8.3) | 0.98 | 2 (9.1) |
Drugs (n, %): NorepinephrineDobutamine Corticosteroids Immunosuppressants | 10 (100) 10 (100) 2 (20) 0 (0) | 12 (100) 12 (100) 2 (16.6) 0 (0) | 0.99 | 22 (100) 22 (100) 4 (18.2) 0 (0) |
Etiologic diagnosis (n, %): Viral Autoimmune Idiopathic | 2 (20) 2 (20) 6 (60) | 2 (16.7) 0 (0) 10 (83.3) | 0.56 | 4 (18.2) 2 (9.1) 16 (72.7) |
Recovery (n = 10) | No Recovery (n = 12) | p | Total (n = 22) | |
---|---|---|---|---|
Echocardiographic parameters at admission: LVEF (%) * LVEF with severe dysfunction (n, %) RV severe dysfunction (n, %) PASP * | 17.4 ± 7.6 10 (100) 5 (50) 30.6 ± 3.4 | 12.6 ± 6.7 12 (100) 8 (66.6) 41.2 ± 4.7 | 0.19 0.98 0.54 0.06 | 14.8 ± 7.3 22 (100) 13 (591) 36.4 ± 6.7 |
Laboratory parameters at admission: * Creatinine (mg/dL)GFR (mL/min) Bilirubin (mg/dL) AST (GOT) (U/L) ALT (GPT) (U/L) Lactate (mmol/L) NT-proBNP (pg/mL) Troponin (pg/mL) Leukocytes (cells/µL) C-reactive protein (mg/L) | 1.6 ± 0.7 56.6 ± 25.6 1.7 ± 1.3 1471 ± 3192 1902 ± 3789 5.5 ± 3.9 20,351 ± 12,652 3337 ± 3371 17,487 ± 8364 138 ± 136 | 1.4 ± 0.7 60.3 ± 36.8 1.8 ± 1.4 3084 ± 4147 1801 ± 2157 8.8 ± 6.1 23,711 ± 11,473 5993 ± 6851 14,048 ± 5407 111 ± 108 | 0.58 0.82 0.87 0.32 0.93 0.20 0.52 0.27 0.25 0.59 | 1.5 ± 0.7 58.6 ± 31.6 1.75 ± 1.3 2325 ± 3847 1847 ± 2942 7.3 ± 5.4 22,130 ± 12,011 4789 ± 5555 15,687 ± 6986 123 ± 121 |
Recovery (n = 10) | No Recovery (n = 12) | p | Total (n = 22) | |
---|---|---|---|---|
Echocardiographic parameters *#: LVEF (%) * LVEF with severe dysfunction (n,%) RV severe dysfunction (n, %) | 51.1 ± 13.1 1 (10) 0 (0) | 29.5 ± 23.2 8 (67) 7 (58.3) | 0.04 <0.01 0.01 | 39.3 ± 20.4 9 (40.9) 7 (31.8) |
Laboratory parameters at discharge: * Creatinine (mg/dL) GFR (mL/min) Bilirubin (mg/dL) AST (GOT) (U/L) ALT (GPT) (U/L) Lactate (mmol/L) NT-proBNP (pg/mL) Troponin (pg/mL) Leukocytes (cells/µL) C-reactive protein (mg/L) | 0.7 ± 0.2 104 ± 17 0.6 ± 0.2 34.1 ± 7.7 52 ± 34 0.8 ± 0.2 1981 ± 2314 190 ± 384 8828 ± 2538 23 ± 18 | 1.2 ± 0.6 69 ± 36 2.1 ± 2.4 1361 ± 2804 919 ± 2068 4.3 ± 5.8 15,687 ± 14,974 1741 ± 3017 18,485 ± 11,009 98 ± 96 | 0.01 0.02 0.07 0.12 0.17 0.08 <0.01 0.10 0.01 0.02 | 1.0 ± 0.5 85.6 ± 31.6 1.4 ± 1.9 748 ± 1943 531 ± 1443 2.7 ± 4.4 9266 ± 11,465 1034 ± 2043 14,188 ± 8370 63 ± 74 |
Recovery (n = 10) | No Recovery (n = 12) | p | Total (n = 22) | |
---|---|---|---|---|
Heart transplant (n, %) | 0 (0) | 4 (33.3) | <0.01 | 4 (18.2) |
Days from inclusion in heart transplant waiting list to transplant * | - | 5.3 ± 5.2 | 5.3 ± 5.2 | |
ICU stay (days) * | 18.4 ± 11.9 | 23.2 ± 18.8 | 0.24 | 21.1 ± 16.1 |
Days to recovery (discharge)/death * | 33.4 ± 17.7 | 35.9 ± 28.9 | 0.31 | 34.8 ± 24.1 |
Complications (n, %): Renal failure Vascular complications Reoperations DVT/PE Tracheotomy Severe neuromyopathy Sepsis | 4 (40) 5 (50) 1 (10) 0 (0) 1 (10) 3 (30) 3 (30) | 8 (67) 10 (83.3) 6 (50) 0 (0) 1 (8) 4 (33) 4 (33) | 0.19 0.07 0.04 0.99 0.71 0.61 0.61 | 12 (54.5) 15 (68.2) 7 (31.8) 0 (0) 2 (9.1) 7 (31.8) 7 (31.8) |
In-hospital survival (n, %) | 10 (100) | 4 (33.3) | <0.01 | 14 (63.6) |
1-year survival (n, %) | 9 (90) | 4 (33.3) | 0.02 | 13 (59) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Guerrero Cervera, B.; López-Vilella, R.; Gimeno Costa, R.; Pérez Esteban, F.; Pérez Guillén, M.; Madrid, I.; Donoso Trenado, V.; Martínez-Solé, J.; Castellanos, Á.; Martínez Dolz, L.; et al. Fulminant Myocarditis with VA-ECMO Support: Clinical Characteristics and Prognosis in a Cohort from a Tertiary Transplant Center. Biomedicines 2025, 13, 2146. https://doi.org/10.3390/biomedicines13092146
Guerrero Cervera B, López-Vilella R, Gimeno Costa R, Pérez Esteban F, Pérez Guillén M, Madrid I, Donoso Trenado V, Martínez-Solé J, Castellanos Á, Martínez Dolz L, et al. Fulminant Myocarditis with VA-ECMO Support: Clinical Characteristics and Prognosis in a Cohort from a Tertiary Transplant Center. Biomedicines. 2025; 13(9):2146. https://doi.org/10.3390/biomedicines13092146
Chicago/Turabian StyleGuerrero Cervera, Borja, Raquel López-Vilella, Ricardo Gimeno Costa, Francisca Pérez Esteban, Manuel Pérez Guillén, Isabel Madrid, Víctor Donoso Trenado, Julia Martínez-Solé, Álvaro Castellanos, Luis Martínez Dolz, and et al. 2025. "Fulminant Myocarditis with VA-ECMO Support: Clinical Characteristics and Prognosis in a Cohort from a Tertiary Transplant Center" Biomedicines 13, no. 9: 2146. https://doi.org/10.3390/biomedicines13092146
APA StyleGuerrero Cervera, B., López-Vilella, R., Gimeno Costa, R., Pérez Esteban, F., Pérez Guillén, M., Madrid, I., Donoso Trenado, V., Martínez-Solé, J., Castellanos, Á., Martínez Dolz, L., Martínez León, J., Torregrosa, S., & Almenar-Bonet, L. (2025). Fulminant Myocarditis with VA-ECMO Support: Clinical Characteristics and Prognosis in a Cohort from a Tertiary Transplant Center. Biomedicines, 13(9), 2146. https://doi.org/10.3390/biomedicines13092146